Enjoy complimentary customisation on priority with our Enterprise License!
In the human body, sinus refers to a hollow space or channel containing blood or a cavity within the bone. The sinus infection occurring behind the head connecting to the nasal cavity, is termed as sinusitis. Sinusitis occurs when the mucus starts building up in the nose and inflates the sinuses. The accumulation of fluid in sinus is the primary cause of sinusitis as this speeds up the process of germ build-up within sinusitis. Various other sinusitis-causing factors consist of viruses, bacteria, and pollutants. Individuals suffering from sinusitis undergo symptoms such as nasal congestion, soreness around eyes, and drainage of thick yellowish-green discharge from nose or throat. Technavio’s market research analysts have identified that the high volume of individuals being diagnosed with sinusitis is driving the significant drug development for therapeutics for sinusitis in the forthcoming years.
According to this pipeline analysis report, most of the drug development molecules in the pipeline account for the same volume of molecules in the pre-clinical, Phase I, and Phase III drug development stage. Our market research analysts have also identified that almost same amount of drug molecules are under the phase I/II and phase II drug development stage.
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of sinusitis. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are:
In this pipeline report analysis, it is observed that most of the therapeutics are being developed for intranasal, oral, and subcutaneous administration. Oral RoA involves the administration of drug through the mouth cavity. Intranasal RoA involves the administration of the drug through the nasal structure and the subcutaneous RoA involves the administration of the drug below the skin.
According to this pipeline analysis report, two of the molecules that are currently in the drug development pipeline for chondrosarcoma are being developed as monoclonal antibody. These molecules are antibodies made out of identical immune cells that are all clone to a unique parent cell. This pipeline analysis also witnesses same amount of molecules in the biological and small molecules.
Technavio also offers customization on reports based on specific client requirement.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
PART 05: MAJOR REGULATORY AUTHORITIES
PART 06: PIPELINE LANDSCAPE
PART 07: COMPARATIVE ANALYSIS
PART 08: INDICATION ANALYSIS
PART 09: THERAPEUTIC ASSESSMENT (THERAPY BASED)
PART 10: THERAPEUTIC ASSESSMENT (ROA BASED)
PART 11: THERAPEUTIC ASSESSMENT BY TARGET
PART 12: KEY COMPANIES
PART 13: APPENDIX
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.